Additional deaths believed to be associated with one of Foghorn Therapeutics Inc.'s lead candidates led the U.S. FDA to put a full clinical hold on its phase I study in relapsed and/or refractory acute myelogenous leukemia and myelodysplastic syndrome.
Likely to garner attention at the upcoming European Society of Medical Oncology meeting are the MAGE-A4 and PRAME antigens which, although well-known and validated, have proved evasive for drug developers – a situation that may soon change.
Etherna Immunotherapies NV has raised €39 million (US$39 million) in new financing as it pivots to an mRNA-platform strategy. It has added a couple of heavy hitters to its board and its roster of investors, indicating that the move has already gained traction in the marketplace.
Everest Medicines Ltd. has inked an agreement with Gilead Sciences Inc. to pass the latter’s subsidiary, Immunomedics Inc., exclusive rights to develop and commercialize Trodelvy (sacituzumab govitecan) in greater China, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.
A subsidiary of Jiangxi Jemincare Group Co. Ltd. has out-licensed global rights to its androgen receptor degrader JMKX-002992 to Roche Holding AG and its subsidiary Genentech Inc. in a deal worth up to $650 million.
Ferroptosis, a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides, is limited in some tumors. Scientists have identified a glutathione (GSH)-independent axis centered mainly on the ferroptosis suppressor protein 1 (FSP1) as responsible for this suppression.
A proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF) are two ligands of the tumor necrosis factor (TNF) superfamily with a crucial regulatory role in B-cell maturation and differentiation. APRIL and BAFF action occurs through binding to three TNF receptors: TACI (transmembrane activator and Ca2+ modulator interactor), B-cell maturation antigen (BCMA), and BAFF receptor (BAFF-R) with different affinities.
Medshine Discovery has patented pyrimidopyran-containing compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Suzhou Kowloon Hospital Shanghai Jiao Tong University School of Medicine has divulged new Toll-like receptor 7 (TLR-7) agonists reported to be useful for the treatment of cancer and viral infections.
Kyowa Kirin Co. Ltd.’s decision, disclosed July 26, to quit development of the adenosine A2a receptor antagonist KW-6356 for Parkinson’s disease (PD) didn’t do much to flatten interest in the target, still under investigation by other firms in cancer.
RSS
